This pilot research trial studies collecting, analyzing, and storing samples from patients with metastatic, triple negative breast cancer receiving cisplatin. Studying samples of tissue, blood, buccal swab, saliva, and urine in the laboratory from patients receiving cisplatin may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

Investigator

Tony Blau, MD

Location

Seattle Cancer Care Alliance

800-804-8824

Eligibility Criteria (must meet the following to participate in this study)

Patients will have metastatic triple negative breast cancer (TNBC) and are about to receive treatment with single agent cisplatin

Measurable disease as determined by physical exam or imaging

Patients must have tumor suitable for biopsy (as assessed by trained specialists in radiology); patients must be medically fit and willing to undergo repeated tissue biopsies or surgical procedures to get tumor tissue

Written informed consent obtained from subject and ability for subject to comply with the requirements of the study

Procedure-specific signed informed consent prior to initiation of any study-related procedures

Agree to allow their de-identified clinical and laboratory data to be posted to publicly available databases such as database of Genotypes and Phenotypes (dbGaP)

Minorities are included in this protocol

Patients with a prior history of malignancy remain eligible

Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible

Exclusions (conditions that would prevent participation in this study)

It is at the enrolling study oncologist's discretion to decide if a patient is not fit enough to undergo tissue biopsy; presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

Significant bleeding disorder

Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study